Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Related

Vinge advises Axcel and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB.
February 12, 2025

Vinge advised American Industrial Partners (AIP)

Vinge advised American Industrial Partners (AIP) on Swedish law aspects of the carve-out acquisition of the agribusiness equipment operations (FoodTech Equipment) of Munters FoodTech.
February 12, 2025

Vinge has advised Gränges on the refinancing of its sustainability-linked credit facility

Vinge has advised Gränges AB (publ) (“Gränges”), a global leader in aluminium rolling and recycling in selected niches, on the refinancing of its sustainability-linked credit facility, which supports Gränges’ sustainability plan.
February 10, 2025